The FDA has approved AstraZeneca’s Saphnelo autoinjector for subcutaneous self-administration in adults with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy. The ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

Patients with systemic lupus erythematosus (SLE) who received belimumab monotherapy had remission rates, Lupus Low Disease Activity State (LLDAS) attainment, and flare rates comparable to those who ...

Objectives Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (SLE) in China. However, the economic value of these two drugs is unclear. Therefore, this ...

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive LN treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab), ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...

Belimumab autoinjector is now approved and available for pediatric patients with lupus nephritis. The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...